Apontis Pharma AG

XTRA:APPH Stock Report

Market Cap: €83.7m

Apontis Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bruno Wohlschlegel

Chief executive officer

€181.0k

Total compensation

CEO salary percentage59.7%
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure2.6yrs

Recent management updates

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Oct 17
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Jun 18
Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

Apr 05
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

CEO Compensation Analysis

How has Bruno Wohlschlegel's remuneration changed compared to Apontis Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€7m

Mar 31 2024n/an/a

-€9m

Dec 31 2023€181k€108k

-€11m

Compensation vs Market: Bruno's total compensation ($USD190.07K) is below average for companies of similar size in the German market ($USD471.99K).

Compensation vs Earnings: Insufficient data to compare Bruno's compensation with company performance.

CEO

Bruno Wohlschlegel (56 yo)

1.3yrs

Tenure

€180,964

Compensation

Mr. Bruno Wohlschlegel serves as Member of Management Board at Apontis Pharma AG since September 01, 2023 and served as its Chief Executive Officer since September 01, 2023. He is Chairman of Management Bo...

Board Members

NamePositionTenureCompensationOwnership
Edin Hadzic
Member of Supervisory Boardno datano datano data
Olaf Elbracht
Independent Deputy Chairman of Supervisory Board2.6yrsno datano data
Matthias Wiedenfels
Independent Chairman of Supervisory Board2.6yrsno datano data
Christian Bettinger
Member of Supervisory Boardno datano datano data
Anna Picciolo-Lehrke
Independent Member of Supervisory Board2.6yrsno datano data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Board: APPH's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.